Labrière Christophe, Gong Huansheng, Finlay B Brett, Reiner Neil E, Young Robert N
Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada.
Department of Medicine, Division of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada.
Eur J Med Chem. 2017 Jan 5;125:1-13. doi: 10.1016/j.ejmech.2016.09.018. Epub 2016 Sep 9.
Several novel series of compounds were synthesized and evaluated as inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase (PK). PK has been identified as a highly interconnected essential 'hub' protein in MRSA, with structural features distinct from the human homologs which makes it a novel antimicrobial target. Several MRSA PK inhibitors (including the hydrazide 1) were identified using in silico screening combined with enzyme assays and were found to be selective for bacterial enzyme compared to human PK isoforms. Structure-activity relationship (SAR) studies were carried out on the replacement of the hydrazide linker with 3-atoms, 2-atoms and 0-atom linkers and led us to discover more potent compounds with enzyme inhibiting activities in the low nanomolar range and some were found to effectively inhibit bacteria growth in culture with minimum inhibitory concentrations (MIC) as low as 1 μg/mL.
合成了几个新型化合物系列,并对其作为耐甲氧西林金黄色葡萄球菌(MRSA)丙酮酸激酶(PK)抑制剂进行了评估。PK已被确定为MRSA中一个高度互联的必需“枢纽”蛋白,其结构特征与人类同源物不同,这使其成为一个新型抗菌靶点。使用计算机筛选结合酶分析鉴定了几种MRSA PK抑制剂(包括酰肼1),发现它们对细菌酶具有选择性,与人类PK同工型相比。对用3原子、2原子和0原子连接体取代酰肼连接体进行了构效关系(SAR)研究,使我们发现了更有效的化合物,其酶抑制活性在低纳摩尔范围内,并且发现一些化合物在培养中能有效抑制细菌生长,最低抑菌浓度(MIC)低至1μg/mL。